How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?. Issue 2 (December 2019)

• Record Type: Journal Article
• Authors: Morton, Alec; Colson, Abigail; Leporowski, Axel; Trett, Anna; Bhatti, Taimur; Laxminarayan, Ramanan
• Is Part Of: MDM policy & practice. Volume 4:Issue 2(2019)
• Publication Date: 2019-12
• Subjects: antibiotics -- antibiotic resistance -- health technology assessment -- reimbursement; Medicine -- Decision making -- Periodicals; Medicine -- Decision making; Decision Making; Clinical Medicine; Health Policy; Periodicals; Periodicals; Electronic journals; 616.075
• DOI: 10.1177/2381468319892237
• Languages: English
• ISSNs: 2381-4683

Abstract

Antibiotics have revolutionized the treatment of bacterial infections. However, it is widely held that there is underinvestment in antibiotics research and development relative to the socially optimal level for a number of reasons. In this article, we discuss whether existing health technology assessment procedures recognize the full economic and societal value of new antibiotics to patients and society when making reimbursement decisions. We present three recommendations for modelling the unique attributes of value that are specific to novel antibiotics. We find, based on a review of the literature, that some of the value elements proposed by our framework have previously been discussed qualitatively by health technology assessment bodies when evaluating antibiotics, but are not yet formally captured via modelling. We present a worked example to show how it may be possible to capture these dimensions of value in a more quantitative manner. We conclude by answering the question of the title as follows: the unique attributes of novel antibiotics should be considered in reimbursement decision making, in a way that captures the full range of benefits these important technologies bring to patients, health care systems, and society.